Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Syahru Agung Setiawan has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adverse Prognostic Significance of Activation‐Induced Cytidine Deaminase in Diffuse Large B‐Cell Lymphoma Patients Treated With R‐ CHOP

    by Mardiah Suci Hardianti, Nungki Anggorowati, Syahru Agung Setiawan, Miraz Radhea Bagaskoro, Johan Kurnianda, Kartika Widayati Taroeno‐Hariadi, Ibnu Purwanto, Susanna Hilda Hutajulu

    Background: A number of studies have demonstrated the important role of activation‐induced cytidine deaminase (AID) in the pathogenesis of diffuse large B‐cell lymphoma (DLBCL). AID has been relatively underexplored as a prognostic factor in DLBCL, and its role remains controversial. Aims: This study conducted a comprehensive analysis of the association between AID expression and clinical outcomes in 70 Indonesian patients with DLBCL treated with a standard CHOP ± rituximab regimen. Methods and Results: Immunostaining results showed that AID was expressed in 35.7% of DLBCL samples. Multivariate analysis indicated that positive AID expression was associated with shorter overall survival (OS) specifically among patients receiving a rituximab‐containing regimen, with a hazard ratio of 10.39 (95% CI: 1.93–55.96; p = 0.006). Conclusion: The significant prognostic value of AID in the DLBCL subgroup treated with rituximab—but not in the general DLBCL population or in those not receiving rituximab—underscores the potential relevance of AID expression in DLBCL management and treatment decisions.

  • Open Access

    Correction: Su et al. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Int. J. Mol. Sci. 2023, 24, 7706

    by I-Chang Su, Yu-Kai Su, Syahru Agung Setiawan, Vijesh Kumar Yadav, Iat-Hang Fong, Chi-Tai Yeh, Chien-Min Lin, Heng-Wei Liu


  • Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer

    by Ming-Shou Hsieh, Hang Huong Ling, Syahru Agung Setiawan, Mardiah Suci Hardianti, Iat-Hang Fong, Chi-Tai Yeh, Jia-Hong Chen


  • Open Access

    NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation

    by I-Chang Su, Yu-Kai Su, Syahru Agung Setiawan, Vijesh Kumar Yadav, Iat-Hang Fong, Chi-Tai Yeh, Chien-Min Lin, Heng-Wei Liu

    Glioblastoma multiforme (GBM) is a highly heterogeneous disease with a mesenchymal subtype tending to exhibit more aggressive and multitherapy-resistant features. Glioblastoma stem-cells derived from mesenchymal cells are reliant on iron supply, accumulated with high reactive oxygen species (ROS), and susceptible to ferroptosis. Temozolomide (TMZ) treatment is the mainstay drug for GBM despite the rapid development of resistance in mesenchymal GBM. The main interconnection between mesenchymal features, TMZ resistance, and ferroptosis are poorly understood. Herein, we demonstrated that a subunit of NADPH oxidase, CYBB, orchestrated mesenchymal shift and promoted TMZ resistance by modulating the anti-ferroptosis circuitry Nrf2/SOD2 axis. Public transcriptomic data re-analysis found that CYBB and SOD2 were highly upregulated in the mesenchymal subtype of GBM. Accordingly, our GBM cohort confirmed a high expression of CYBB in the GBM tumor and was associated with mesenchymal features and poor clinical outcome. An in vitro study demonstrated that TMZ-resistant GBM cells displayed mesenchymal and stemness features while remaining resilient to erastin-mediated ferroptosis by activating the CYBB/Nrf2/SOD2 axis. The CYBB maintained a high ROS state to sustain the mesenchymal phenotype, TMZ resistance, and reduced erastin sensitivity. Mechanistically, CYBB interacted with Nrf2 and consequently regulated SOD2 transcription. Compensatory antioxidant SOD2 essentially protected against the deleterious effect of high ROS while attenuating ferroptosis in TMZ-resistant cells. An animal study highlighted the protective role of SOD2 to mitigate erastin-triggered ferroptosis and tolerate oxidative stress burden in mice harboring TMZ-resistant GBM cell xenografts. Therefore, CYBB captured ferroptosis resilience in mesenchymal GBM. The downstream compensatory activity of CYBB via the Nrf2/SOD2 axis is exploitable through erastin-induced ferroptosis to overcome TMZ resistance.


  • Open Access

    KDM5D Histone Demethylase Identifies Platinum-Tolerant Head and Neck Cancer Cells Vulnerable to Mitotic Catastrophe

    by Tsung-Ming Chen, Chih-Ming Huang, Syahru Agung Setiawan, Ming-Shou Hsieh, Chih-Chi Sheen, Chi-Tai Yeh

    Head and neck squamous cell carcinoma (HNSCC) is a major contributor to cancer incidence globally and is currently managed by surgical resection followed by adjuvant chemoradiotherapy. However, local recurrence is the major cause of mortality, indicating the emergence of drug-tolerant persister cells. A specific histone demethylase, namely lysine-specific demethylase 5D (KDM5D), is overexpressed in diverse types of cancers and involved in cancer cell cycle regulation. However, the role of KDM5D in the development of cisplatin-tolerant persister cells remains unexplored. Here, we demonstrated that KDM5D contributes to the development of persister cells. Aurora Kinase B (AURKB) disruption affected the vulnerability of persister cells in a mitotic catastrophe–dependent manner. Comprehensive in silico, in vitro, and in vivo experiments were performed. KDM5D expression was upregulated in HNSCC tumor cells, cancer stem cells, and cisplatin-resistant cells with biologically distinct signaling alterations. In an HNSCC cohort, high KDM5D expression was associated with a poor response to platinum treatment and early disease recurrence. KDM5D knockdown reduced the tolerance of persister cells to platinum agents and caused marked cell cycle deregulation, including the loss of DNA damage prevention, and abnormal mitosis-enhanced cell cycle arrest. By modulating mRNA levels of AURKB, KDM5D promoted the generation of platinum-tolerant persister cells in vitro, leading to the identification of the KDM5D/AURKB axis, which regulates cancer stemness and drug tolerance of HNSCC. Treatment with an AURKB inhibitor, namely barasertib, resulted in a lethal consequence of mitotic catastrophe in HNSCC persister cells. The cotreatment of cisplatin and barasertib suppressed tumor growth in the tumor mouse model. Thus, KDM5D might be involved in the development of persister cells, and AURKB disruption can overcome tolerance to platinum treatment in HNSCC.


  • Phenethyl isothiocyanate inhibits CD133+/CD90+ liver cancer stem cells by modulation of microRNA‐214‐β‐catenin epigenome axis

    by Yi C. Chu, Sheng‐Tsai Lin, Syahru A. Setiawan, Ming‐Shou Hsieh, Vijesh K. Yadav, Ting‐Yi Huang, Chi‐Tai Yeh, Ming‐Yao Chen

    Hepatocellular carcinoma (HCC) represents one of the most prevalent and lethal type of malignancies around the globe. Despite the advancement in medical research and therapeutics development, HCC still remains a taunting challenge in clinical settings. Recent studies indicate that the presence of cancer stem cells (CSCs) may be the underlying factor for treatment failure, distant metastasis, and disease recurrence. Elevated stemness gene expression has been correlated to disease stage and poorer prognosis in HCC patients. Initially, we established that β‐catenin is highly expressed in HCC clinical samples. We subsequently re‐validated the idea that CD133+/CD90+ subpopulation cells exhibited CSCs properties including elevated stemness expression (β‐catenin, Nanog, c‐Myc, and Twist1), increased self‐renewal capacity and metastatic potential. Using this cell model, we tested the potential anti‐CSCs effects of phenethyl isothiocynanate (PEITC), a phytochemical isolated from cruciferous vegetables. Treatment of PEITC led to a decreased percentage of CD133+/CD90+ cells in both Huh7 and Sk‐Hep1 cell lines. In addition, PEITC suppressed stemness gene expression, self‐renewal ability, and metastatic potential in HCC CSCs. Mechanistically, PEITC conveyed its anti‐CSCs effects via upregulating microRNA‐214, a negative regulator of β‐catenin. In conclusion, we provided evidence that PEITC could suppress HCC CSCs generation/maintenance. With further clinical testing, PEITC could be used either alone or in combination with currently available chemotherapeutic agents to achieve improved efficacy.


  • Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma

    by Syahru Agung Setiawan, Winston Zhenhao Liu, Pei‐Wei Weng, Chia-Hwa Lee, Vijesh Kumar Yadav, Mardiah Suci Hardianti, Chi-Tai Yeh, Tsu-Yi Chao


  • Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways

    by Chia-Hung Hsu, Pei‐Wei Weng, Ming-Yao Chen, Chi-Tai Yeh, Syahru Agung Setiawan, Vijesh Kumar Yadav, Alexander T.H. Wu, David T.W. Tzeng, Jian-Xian Gong, Zhen Yang, et al.


  • Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis

    by Ming-Yao Chen, Chia-Hung Hsu, Syahru Agung Setiawan, David T.W. Tzeng, Hon-Ping Ma, Jiann Ruey Ong, Yi Cheng Chu, Ming-Shou Hsieh, Alexander T.H. Wu, Yew-Min Tzeng, et al.


  • Open Access

    Targeting the SREBP-1/Hsa-Mir-497/SCAP/FASN Oncometabolic Axis Inhibits the Cancer Stem-like and Chemoresistant Phenotype of Non-Small Cell Lung Carcinoma Cells

    by Tung-Yu Tiong, Pei-Wei Weng, Chun-Hua Wang, Syahru Agung Setiawan, Vijesh Kumar Yadav, Narpati Wesa Pikatan, Iat-Hang Fong, Chi-Tai Yeh, Chia-Hung Hsu, Kuang-Tai Kuo

    Background: Lung cancer remains a leading cause of cancer-related death, with an annual global mortality rate of 18.4%. Despite advances in diagnostic and therapeutic technologies, non–small cell lung carcinoma (NSCLC) continues to be characterized by a poor prognosis. This may be associated with the enrichment of cancer stem cells (CSCs) and the development of chemoresistance—a double-edged challenge that continues to impede the improvement of long-term outcomes. Metabolic reprogramming is a new hallmark of cancer. Sterol regulatory element-binding proteins (SREBPs) play crucial regulatory roles in the synthesis and uptake of cholesterol, fatty acids, and phospholipids. Recent evidence has demonstrated that SREBP-1 is upregulated in several cancer types. However, its role in lung cancer remains unclear. Objective: This study investigated the role of SREBP-1 in NSCLC biology, progression, and therapeutic response and explored the therapeutic exploitability of SREBP-1 and SREBP-1-dependent oncometabolic signaling and miRNA epigenetic regulation. Methods: We analyzed SREBP-1 levels and biological functions in clinical samples and the human NSCLC cell lines H441 and A549 through shRNA-based knock down of SREBP function, cisplatin-resistant clone generation, immunohistochemical staining of clinical samples, and cell viability, sphere-formation, Western blot, and quantitative PCR assays. We conducted in-silico analysis of miRNA expression in NSCLC samples by using the Gene Expression Omnibus (GSE102286) database. Results: We demonstrated that SREBP-1 and SCAP are highly expressed in NSCLC and are positively correlated with the aggressive phenotypes of NSCLC cells. In addition, downregulation of the expression of tumor-suppressing hsa-miR-497-5p, which predictively targets SREBP-1, was observed. We also demonstrated that SREBP-1/SCAP/FASN lipogenic signaling plays a key role in CSCs-like and chemoresistant NSCLC phenotypes, especially because the fatostatin or shRNA targeting of SREBP-1 significantly suppressed the viability, cisplatin resistance, and cancer stemness of NSCLC cells and because treatment induced the expression of hsa-miR-497. Conclusion: Targeting the SREBP-1/hsa-miR-497 signaling axis is a potentially effective anticancer therapeutic strategy for NSCLC.